Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

326.85 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Barron's Weekend Stock Picks: Chevron, Apple, Disney And Insulet's Stock Increase
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. 
Via Benzinga
Insulet Surges After Eye-Popping Earnings Growth Wallops Expectations
Insulet makes an insulin pump called Omnipod. U.S. sales are on the rise. 
Via Investor's Business Daily
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Expert Ratings for Insulet
 
Via Benzinga
Why Shares of Insulet Dropped This Week
Positive news regarding diabetes therapy Ozempic worried investors. 
Via The Motley Fool
14 Analysts Have This to Say About Insulet
 
Via Benzinga
Why Insulet Stock Is Sinking Today
Comments from Insulet's CEO at a major healthcare conference rattled investors. 
Via The Motley Fool
Omnipod Insulin Pump Working Well For Insulet, Lifts Annual Forecast
Insulet Corporation (NASDAQ: PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the  
Via Benzinga
Insulet Reports Third Quarter 2023 Revenue Increase of 27% Year-Over-Year (25% Constant Currency1)
From Insulet Corporation
Via Business Wire
Insulet Spotlights Diabetes Awareness on World Diabetes Day and Throughout November
From Insulet Corporation
Via Business Wire
Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?
Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story. 
Via Investor's Business Daily
Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone
From Insulet Corporation
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Why Insulet Stock Traded Lower
Insulet Corporation (NASDAQ: PODD) shares traded lower Thursday. 
Via Benzinga
Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories
Benzinga 
Via Benzinga
Are the S&P 500's Biggest Q3 Losers Next Year's Winners?
More than 70% of S&P 500 stocks finished in the red last quarter, but the broad-based selloff may be an opportunity - including for these three biggest losers. 
Via MarketBeat
Topics Artificial Intelligence Economy Stocks
Tubeless Insulin Pump Technology Provider Insulet's CFO Resigns; Reaffirms Q3, FY23 Outlook
Medical device company Insulet Corp (NASDAQ: PODD) disclosed that Wayde McMillan has decided to resign as Executive Vice President,  
Via Benzinga
Insulet Announces CFO Transition
From Insulet Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023
 
Via Benzinga
FedEx To Rally Around 19%? Here Are 10 Other Analyst Forecasts For Monday
JP Morgan raised the price target for The Progressive Corporation (NYSE: PGR) from $146 to $149. JP Morgan analyst Jimmy Bhullar maintained an Overweight rating. Progressive shares fell 0.8% to close... 
Via Benzinga
Insulet to Present Extended Real-World Evidence and Best Practices for Optimizing Care with Omnipod® 5
From Insulet Corporation
Via Business Wire
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
The broad-market index is up but these stocks are down. 
Via The Motley Fool
Topics Stocks
Insulet to Announce Third Quarter 2023 Financial Results on November 2, 2023
From Insulet Corporation
Via Business Wire
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
The September market downturn is spreading like wildfire across various sectors, with only a handful of stocks managing to maintain the positive trend seen in recent months. 
Via Benzinga
Topics Stocks
Navigating The S&P 500 Landscape: Here Are The Stocks Analysts Believe Have The Highest Potential And Biggest Downside
In the middle of the AI revolution and the Federal Reserve's steadfast stance on interest rates, the stock market has seen unexpected twists and turns. Despite hopes of the U.S. 
Via Benzinga
Topics Artificial Intelligence Stocks
The 7 Most Undervalued Stocks in the Market Right Now: September 2023
Buying these undervalued stocks right now can pay off tremendously once these fundamentally solid businesses ultimately recover. 
Via InvestorPlace
Apple Taps Seasoned Executive To Head 'Secret' Team Developing Glucose Monitoring Device - Stocks To Watch
Apple Inc (NASDAQ: AAPL) has appointed Tim Millet, a seasoned executive with a background in iPhone and Mac chip technology, to oversee its secretive team dedicated to developing a noninvasive blood... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
Why Toro Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) shares jumped 100% to $1.7909 after the company's subsidiary Champion Safe has been bombarded with calls from safe dealers and customers looking for... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.